Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...